Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
- PMID: 19720927
- DOI: 10.1200/JCO.2008.19.8721
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Abstract
Purpose: We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
Patients and methods: One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m(2) or 125 mg/m(2) (with or without concomitant enzyme-inducing antiepileptic drugs, respectively) once every 2 weeks. Primary end points were 6-month progression-free survival and objective response rate, as determined by independent radiology review. Secondary end points included safety and overall survival.
Results: In the bevacizumab-alone and the bevacizumab-plus-irinotecan groups, estimated 6-month progression-free survival rates were 42.6% and 50.3%, respectively; objective response rates were 28.2% and 37.8%, respectively; and median overall survival times were 9.2 months and 8.7 months, respectively. There was a trend for patients who were taking corticosteroids at baseline to take stable or decreasing doses over time. Of the patients treated with bevacizumab alone or bevacizumab plus irinotecan, 46.4% and 65.8%, respectively, experienced grade > or = 3 adverse events, the most common of which were hypertension (8.3%) and convulsion (6.0%) in the bevacizumab-alone group and convulsion (13.9%), neutropenia (8.9%), and fatigue (8.9%) in the bevacizumab-plus-irinotecan group. Intracranial hemorrhage was noted in two patients (2.4%) in the bevacizumab-alone group (grade 1) and in three patients (3.8%) patients in the bevacizumab-plus-irinotecan group (grades 1, 2, and 4, respectively).
Conclusion: Bevacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma.
Trial registration: ClinicalTrials.gov NCT00345163.
Republished in
-
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.J Clin Oncol. 2023 Nov 10;41(32):4945-4952. doi: 10.1200/JCO.22.02772. J Clin Oncol. 2023. PMID: 37935104 Clinical Trial.
Comment in
-
Bevacizumab and recurrent malignant gliomas: a European perspective.J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2. doi: 10.1200/JCO.2009.26.9027. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159801 No abstract available.
Similar articles
-
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.J Clin Oncol. 2023 Nov 10;41(32):4945-4952. doi: 10.1200/JCO.22.02772. J Clin Oncol. 2023. PMID: 37935104 Clinical Trial.
-
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5. Neuro Oncol. 2010. PMID: 20406901 Free PMC article. Clinical Trial.
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.J Clin Oncol. 2009 Feb 10;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. Epub 2008 Dec 29. J Clin Oncol. 2009. PMID: 19114704 Free PMC article. Clinical Trial.
-
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.BMC Cancer. 2010 Jun 2;10:252. doi: 10.1186/1471-2407-10-252. BMC Cancer. 2010. PMID: 20525214 Free PMC article. Review.
-
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13. Med Oncol. 2010. PMID: 19526201 Review.
Cited by
-
Neuroinflammation in Glioblastoma: Progress and Perspectives.Brain Sci. 2024 Jul 9;14(7):687. doi: 10.3390/brainsci14070687. Brain Sci. 2024. PMID: 39061427 Free PMC article. Review.
-
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.Clin Cancer Res. 2024 Aug 1;30(15):3167-3178. doi: 10.1158/1078-0432.CCR-23-4098. Clin Cancer Res. 2024. PMID: 38836759 Clinical Trial.
-
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.Strahlenther Onkol. 2024 Sep;200(9):805-814. doi: 10.1007/s00066-024-02242-6. Epub 2024 Jun 3. Strahlenther Onkol. 2024. PMID: 38829437
-
A Unique Case of a Patient With Pancreatic Cancer Developing Leptomeningeal Metastases While on Gemcitabine and Nab-Paclitaxel.Cureus. 2024 Apr 12;16(4):e58139. doi: 10.7759/cureus.58139. eCollection 2024 Apr. Cureus. 2024. PMID: 38738113 Free PMC article.
-
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma.medRxiv [Preprint]. 2024 Apr 24:2024.04.23.24304634. doi: 10.1101/2024.04.23.24304634. medRxiv. 2024. PMID: 38712133 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical